Bio-Medical Applications Of Tennessee, Inc. is a medicare approved dialysis facility center in Centerville, Tennessee and it has 13 dialysis stations. It is located in Hickman county at 193 Brown Junction Road, Centerville, TN, 37033. You can reach out to the office of Bio-Medical Applications Of Tennessee, Inc. at (931) 729-0810. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Bio-Medical Applications Of Tennessee, Inc. has the following ownership type - Profit. It was first certified by medicare in August, 2008. The medicare id for this facility is 442675 and it accepts patients under medicare ESRD program.
| Name | Bio-Medical Applications Of Tennessee, Inc. |
|---|---|
| Location | 193 Brown Junction Road, Centerville, Tennessee |
| No. of Dialysis Stations | 13 |
| Medicare ID | 442675 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 193 Brown Junction Road, Centerville, Tennessee, 37033 | |
| (931) 729-0810 | |
News Archive
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy.
The current study examines children in pediatric ICU (PICU) care with COVID-19. Read more here.
Qosina is pleased to announce the addition of four new winged female luer lock to barb connectors (#11760-#11763), in stock and ready for immediate delivery.
New data suggest that the accumulation of genetic changes is not solely determined by natural selection. A study by University of Chicago researchers contradicts conventional theory by showing that the percentage of mutations accepted in evolution is also strongly swayed by the speed at which new mutations arrive at a gene: the faster the speed of new mutations, the greater the percentage of those mutations accepted.
The Financial Times has published a special report, titled "Combating Tuberculosis 2013," as World TB Day on March 24 approaches.
› Verified 3 days ago
| NPI Number | 1447470513 |
| Organization Name | Fresenius Medical Care Centerville |
| Doing Business As | Bio-medical Applications Of Tennessee, Inc. |
| Address | 193 Brown Junction Lane Centerville, Tennessee, 37033 |
| Phone Number | (931) 729-0810 |
News Archive
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy.
The current study examines children in pediatric ICU (PICU) care with COVID-19. Read more here.
Qosina is pleased to announce the addition of four new winged female luer lock to barb connectors (#11760-#11763), in stock and ready for immediate delivery.
New data suggest that the accumulation of genetic changes is not solely determined by natural selection. A study by University of Chicago researchers contradicts conventional theory by showing that the percentage of mutations accepted in evolution is also strongly swayed by the speed at which new mutations arrive at a gene: the faster the speed of new mutations, the greater the percentage of those mutations accepted.
The Financial Times has published a special report, titled "Combating Tuberculosis 2013," as World TB Day on March 24 approaches.
› Verified 3 days ago
| Dialysis patients with Hemoglobin data | 17 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 18 |
News Archive
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy.
The current study examines children in pediatric ICU (PICU) care with COVID-19. Read more here.
Qosina is pleased to announce the addition of four new winged female luer lock to barb connectors (#11760-#11763), in stock and ready for immediate delivery.
New data suggest that the accumulation of genetic changes is not solely determined by natural selection. A study by University of Chicago researchers contradicts conventional theory by showing that the percentage of mutations accepted in evolution is also strongly swayed by the speed at which new mutations arrive at a gene: the faster the speed of new mutations, the greater the percentage of those mutations accepted.
The Financial Times has published a special report, titled "Combating Tuberculosis 2013," as World TB Day on March 24 approaches.
› Verified 3 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 30 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 218 |
| Percentage of adult patients getting regular hemodialysis at the center | 100 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy.
The current study examines children in pediatric ICU (PICU) care with COVID-19. Read more here.
Qosina is pleased to announce the addition of four new winged female luer lock to barb connectors (#11760-#11763), in stock and ready for immediate delivery.
New data suggest that the accumulation of genetic changes is not solely determined by natural selection. A study by University of Chicago researchers contradicts conventional theory by showing that the percentage of mutations accepted in evolution is also strongly swayed by the speed at which new mutations arrive at a gene: the faster the speed of new mutations, the greater the percentage of those mutations accepted.
The Financial Times has published a special report, titled "Combating Tuberculosis 2013," as World TB Day on March 24 approaches.
› Verified 3 days ago
| Adult patients getting regular peritoneal dialysis at the center | 7 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 71 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy.
The current study examines children in pediatric ICU (PICU) care with COVID-19. Read more here.
Qosina is pleased to announce the addition of four new winged female luer lock to barb connectors (#11760-#11763), in stock and ready for immediate delivery.
New data suggest that the accumulation of genetic changes is not solely determined by natural selection. A study by University of Chicago researchers contradicts conventional theory by showing that the percentage of mutations accepted in evolution is also strongly swayed by the speed at which new mutations arrive at a gene: the faster the speed of new mutations, the greater the percentage of those mutations accepted.
The Financial Times has published a special report, titled "Combating Tuberculosis 2013," as World TB Day on March 24 approaches.
› Verified 3 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Bio-Medical Applications Of Tennessee, Inc. with elevated calcium levels.
| Patients with hypercalcemia | 38 |
| Hypercalcemia patient months | 310 |
| Patients with Serumphosphor | 42 |
| Patients with Serumphosphor less than 3.5 mg/dL | 7 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 28 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 28 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 19 |
| Patients with Serumphosphor greater than 7 mg/dL | 18 |
News Archive
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy.
The current study examines children in pediatric ICU (PICU) care with COVID-19. Read more here.
Qosina is pleased to announce the addition of four new winged female luer lock to barb connectors (#11760-#11763), in stock and ready for immediate delivery.
New data suggest that the accumulation of genetic changes is not solely determined by natural selection. A study by University of Chicago researchers contradicts conventional theory by showing that the percentage of mutations accepted in evolution is also strongly swayed by the speed at which new mutations arrive at a gene: the faster the speed of new mutations, the greater the percentage of those mutations accepted.
The Financial Times has published a special report, titled "Combating Tuberculosis 2013," as World TB Day on March 24 approaches.
› Verified 3 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 26 |
| Patient months included in arterial venous fistula and catheter summaries | 197 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 81 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 4 |
News Archive
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy.
The current study examines children in pediatric ICU (PICU) care with COVID-19. Read more here.
Qosina is pleased to announce the addition of four new winged female luer lock to barb connectors (#11760-#11763), in stock and ready for immediate delivery.
New data suggest that the accumulation of genetic changes is not solely determined by natural selection. A study by University of Chicago researchers contradicts conventional theory by showing that the percentage of mutations accepted in evolution is also strongly swayed by the speed at which new mutations arrive at a gene: the faster the speed of new mutations, the greater the percentage of those mutations accepted.
The Financial Times has published a special report, titled "Combating Tuberculosis 2013," as World TB Day on March 24 approaches.
› Verified 3 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 31 |
| Hospitalization Rate in facility | 215.3 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 403.6 |
| Hospitalization Rate: Lower Confidence Limit | 120.7 |
News Archive
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy.
The current study examines children in pediatric ICU (PICU) care with COVID-19. Read more here.
Qosina is pleased to announce the addition of four new winged female luer lock to barb connectors (#11760-#11763), in stock and ready for immediate delivery.
New data suggest that the accumulation of genetic changes is not solely determined by natural selection. A study by University of Chicago researchers contradicts conventional theory by showing that the percentage of mutations accepted in evolution is also strongly swayed by the speed at which new mutations arrive at a gene: the faster the speed of new mutations, the greater the percentage of those mutations accepted.
The Financial Times has published a special report, titled "Combating Tuberculosis 2013," as World TB Day on March 24 approaches.
› Verified 3 days ago
The rate of readmission show you whether patients who were being treated regularly at Bio-Medical Applications Of Tennessee, Inc. were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 27.5 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 40.1 |
| Readmission Rate: Lower Confidence Limit | 16.9 |
News Archive
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy.
The current study examines children in pediatric ICU (PICU) care with COVID-19. Read more here.
Qosina is pleased to announce the addition of four new winged female luer lock to barb connectors (#11760-#11763), in stock and ready for immediate delivery.
New data suggest that the accumulation of genetic changes is not solely determined by natural selection. A study by University of Chicago researchers contradicts conventional theory by showing that the percentage of mutations accepted in evolution is also strongly swayed by the speed at which new mutations arrive at a gene: the faster the speed of new mutations, the greater the percentage of those mutations accepted.
The Financial Times has published a special report, titled "Combating Tuberculosis 2013," as World TB Day on March 24 approaches.
› Verified 3 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Bio-Medical Applications Of Tennessee, Inc. get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 4.62 (Worse than Expected) |
| SIR: Upper Confidence Limit | 9.13 |
| SIR: Lower Confidence Limit | 2.02 |
News Archive
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy.
The current study examines children in pediatric ICU (PICU) care with COVID-19. Read more here.
Qosina is pleased to announce the addition of four new winged female luer lock to barb connectors (#11760-#11763), in stock and ready for immediate delivery.
New data suggest that the accumulation of genetic changes is not solely determined by natural selection. A study by University of Chicago researchers contradicts conventional theory by showing that the percentage of mutations accepted in evolution is also strongly swayed by the speed at which new mutations arrive at a gene: the faster the speed of new mutations, the greater the percentage of those mutations accepted.
The Financial Times has published a special report, titled "Combating Tuberculosis 2013," as World TB Day on March 24 approaches.
› Verified 3 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Bio-Medical Applications Of Tennessee, Inc.'s rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 29 |
| Transfusion Rate in facility | 64.9 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 180 |
| Transfusion Rate: Lower Confidence Limit | 26.5 |
News Archive
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy.
The current study examines children in pediatric ICU (PICU) care with COVID-19. Read more here.
Qosina is pleased to announce the addition of four new winged female luer lock to barb connectors (#11760-#11763), in stock and ready for immediate delivery.
New data suggest that the accumulation of genetic changes is not solely determined by natural selection. A study by University of Chicago researchers contradicts conventional theory by showing that the percentage of mutations accepted in evolution is also strongly swayed by the speed at which new mutations arrive at a gene: the faster the speed of new mutations, the greater the percentage of those mutations accepted.
The Financial Times has published a special report, titled "Combating Tuberculosis 2013," as World TB Day on March 24 approaches.
› Verified 3 days ago
The rate of mortality show you whether patients who were being treated regularly at Bio-Medical Applications Of Tennessee, Inc. lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 132 |
| Mortality Rate in facility | 24.5 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 35.4 |
| Mortality Rate: Lower Confidence Limit | 16.3 |
News Archive
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy.
The current study examines children in pediatric ICU (PICU) care with COVID-19. Read more here.
Qosina is pleased to announce the addition of four new winged female luer lock to barb connectors (#11760-#11763), in stock and ready for immediate delivery.
New data suggest that the accumulation of genetic changes is not solely determined by natural selection. A study by University of Chicago researchers contradicts conventional theory by showing that the percentage of mutations accepted in evolution is also strongly swayed by the speed at which new mutations arrive at a gene: the faster the speed of new mutations, the greater the percentage of those mutations accepted.
The Financial Times has published a special report, titled "Combating Tuberculosis 2013," as World TB Day on March 24 approaches.
› Verified 3 days ago
Bio-Medical Applications Of Tennessee, Inc. Location: 193 Brown Junction Road, Centerville, Tennessee, 37033 Phone: (931) 729-0810 |
News Archive
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy.
The current study examines children in pediatric ICU (PICU) care with COVID-19. Read more here.
Qosina is pleased to announce the addition of four new winged female luer lock to barb connectors (#11760-#11763), in stock and ready for immediate delivery.
New data suggest that the accumulation of genetic changes is not solely determined by natural selection. A study by University of Chicago researchers contradicts conventional theory by showing that the percentage of mutations accepted in evolution is also strongly swayed by the speed at which new mutations arrive at a gene: the faster the speed of new mutations, the greater the percentage of those mutations accepted.
The Financial Times has published a special report, titled "Combating Tuberculosis 2013," as World TB Day on March 24 approaches.
› Verified 3 days ago